

CONFIDENTIAL



NOTIFICATION PURSUANT TO

18 V.S.A. § 4637(c)

Subject: Notification Pursuant to 18 V.S.A. § 4637(c)

To the Office of the Attorney General of Vermont:

On June 10, 2019, Genentech USA, Inc. (“Genentech”) notified the Office of the Attorney General of Vermont of a new prescription drug (Polivy 140mg Vial), pursuant to § 4637(b). Genentech hereby notifies the Attorney General of Vermont of the following additional information, pursuant to § 4637(c):

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	WAC (Wholesale Acquisition Cost) (As of the Date of Commercial Availability)
Polivy 140mg Vial	50242-0105-01	June 10, 2019	\$15,000.00

Description of the marketing and pricing plans used in the launch of Polivy 140mg Vial in the United States and internationally:

Marketing activities that support the launch of a new medicine are designed to raise awareness and understanding with healthcare providers and - in some cases - patients about the approved indication(s), efficacy and safety data contained within the medicine's FDA approved label.

We take decisions related to the prices of our medicines very seriously. When determining pricing, we consider a number of factors including: how well the medicine works and how it compares to other available treatments; the financial resources required to continue discovering new medicines for people with serious diseases; and how to ensure that the price doesn't prevent our medicines getting to people who need them.

Polivy 140mg Vial was granted priority review and breakthrough therapy designation.

The estimated volume of patients who may be prescribed Polivy 140mg Vial:
Genentech does not publicly disclose the estimated volume of patients who may be prescribed Polivy 140mg Vial.

The date and price of acquisition if the drug was not developed by the manufacturer:
Polivy 140mg Vial was not co-developed or acquired from a third party.

Sincerely,

Maria Aquilina
Director, Government Programs
Genentech USA, Inc.